Xenon Pharmaceuticals (XENE) Misses Q3 EPS by 6c

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q3 EPS of ($0.57), $0.06 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $130 thousand versus the consensus estimate of $4.15 million.

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• The LGL Group (LGL) Misses Q2 EPS by 8c
• Is Treasury selloff a major issue for stock market bulls?